Error loading player: No playable sources found
M103
EFPIA Biomanufacturing Satellite Session: AAV: Current Status, Manufacturing Challenges and Opportunities
Date
May 11, 2020
This product is not available for individual purchase, but it is available as part of the following products:
The purpose of the CMC Strategy Forum Europe 2020 is to offer a blend of topics that characterize the challenges facing the biotechnology industry in the next decade…
Chairs
Novartis Pharma AG
Eli Lilly Kinsale Limited
Speakers
Pall Life Sciences
uniQure, N.V
BASG-Federal Office for Safety in Health Care
The Rockefeller University
Tracks
Related Products
Regulator’s Perspective on AAV
Scientific literature shows that, recombinant AAV vectors derived from human- versus insect cell manufacturing platforms exhibit significant different potency. The causes for these differences seem currently not entirely clear…
Intensifying the Viral Vector Manufacturing Process: Challenges and Progress
With several recent FDA approvals and a strong drug pipeline, gene therapy is coming of age. With this comes the requirement to ensure that there are robust manufacturing processes in place in order to scale with demand and to make these therapies readily accessible to those who need them…
